How far away are intellectual property rights?
Release time:
2020-08-14
How far is intellectual property from us?
In 2016 , a piece of news called "Huawei's counterattack to Apple to collect royalties" once became a hot topic in the community. Although this news has been circulating in the small circle of the mobile phone industry for a long time, it is absolutely new to the common people-Apple, the top company in the mobile phone industry, has to pay money to Huawei?
According to the licensing registration information published by the State Intellectual Property Office, Huawei licensed 769 patents to Apple in 2015 , and Apple licensed 98 patents to Huawei. Judging from the widely different figures, it is not too much to call it "counter attack. Some people may think that this is because of technology transfer between peers, but in fact, even if Huawei does not have a mobile phone business, Apple will still pay a lot of fees to it, because as a global mainstream telecom equipment supplier, Huawei holds many necessary patents for the 4G standard. In the same way, the reason why Huawei has been able to develop rapidly in the mobile phone business is not only its own patent advantages, but also an important reason for paying fees to patent giants such as Apple and Ericsson to obtain authorization.
From this example, it is not difficult to see that intellectual property, an intangible asset, can be transformed into tangible economic benefits as long as it has certain advantages and is used properly.
Some people may say that network communication is a knowledge-intensive industry with high technology content. It is normal to have many inventions and patents. The main business of peak is traditional manufacturing. When it comes to pharmaceutical industry and research and development of new products, if it is a cement industry with very mature technology, it is too far away from the words "scientific research", "invention" and "patent. However, in the intellectual property knowledge training organized by the company on 11 22 , some examples cited by the teacher subverted this concept-many domestic cement enterprises have more than 100 independent invention patents, which are no less than those owned by Jianfeng Pharmaceutical. This simple comparison of figures is enough to show that our previous understanding of the concept of "intellectual property" is still too superficial, and there are many deficiencies in the work on intellectual property.
According to the official interpretation, intellectual property is the ownership of the results of intellectual labor, which is the exclusive right granted to qualified authors, inventors or owners of the results for a certain period of time in accordance with the laws of various countries. Intellectual property rights are mainly divided into two categories: copyright and industrial property rights. Among them, industrial property rights that are closely related to business operations can be divided into trademark rights and patent rights. As a company with well-known trademarks in China and well-known trademarks in Zhejiang Province, we are relatively familiar with trademark rights in our daily work, and we have also done a lot of work in combating trademark infringement and maintaining market stability; but for patent rights, many people still think That is Edison's "business scope". In fact, this idea is not only wrong, but also a great underestimate of our own ability.
According to China's "Patent Law", there are three types of inventions, inventions, utility models and designs. Let's not talk about the "invention" that looks very "tall". In terms of "utility model", it refers to "a new technical scheme suitable for practicality proposed for the shape, structure or combination of the product". That is to say, whether it is Jianfeng Pharmaceutical or cement, as one of the daily key tasks, technological transformation, process innovation, formula adjustment and process optimization, they are all covered by "utility models"; small inventions and small creations that we have made in recent years to promote "three reductions and three improvements" may become patents; even, every rationalization proposal put forward by employees, Every small innovation carried out may make them the owners of patent rights. As for the design patent, it gives us more room to think.
In today's era of knowledge explosion and rapid development of science and technology, new technologies and new achievements emerge one after another, and the speed of transformation, update and elimination of achievements is greatly accelerated. It is impossible for any enterprise or industry to develop behind closed doors. It is bound to overlap with other industries and other enterprises, especially the application of new technologies and new achievements. In this context, it is almost impossible to invent and create in the "nothing" style like Edison's time. Perhaps because of this, although we are thinking and implementing innovations and improvements every day, and have achieved results and produced practical results in practical applications, most of the intellectual property rights and their derivative values of these results lack sufficient attention.
The current market competition is multifaceted. Although intellectual property rights are intangible "soft power", they often produce "hard effects" that establish competitive advantages ". In recent years, the company has paid more and more attention to intellectual property work such as brand management and patent declaration, but compared with outstanding companies in the same industry, there is indeed a big gap. The implementation of intellectual property strategy focuses on cultivating the awareness and means of supporting enterprises in the protection and utilization of intellectual property rights, and guiding enterprises to enhance their ability to create, utilize, manage and operate intellectual property rights in the market competition. Therefore, while constantly innovating and catching up with others, we should also carefully sort out what we have done and see what we have overlooked over the years that could have been more shining. (Hong Tao)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31